Boehringer Ingelheim v. Granules India: Linagliptin ANDA Blocked by Consent Judgment
Boehringer Ingelheim and its affiliates sued Granules India in Delaware over two linagliptin patents covering a 5 mg tablet formulation. The case resolved in just 113 days when Granules agreed to a consent judgment — conceding patent validity and accepting an injunction barring its ANDA product until both patents expire, including any term extensions.
Granules India yields early: linagliptin ANDA blocked through patent expiry
In June 2024, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG, and Boehringer Ingelheim International GmbH filed a Hatch-Waxman ANDA infringement action in the District of Delaware against Granules India Limited. The suit asserted two patents — US9486526B2 and US10034877B2 — covering linagliptin 5 mg tablets, the active ingredient in Tradjenta, a widely prescribed type-2 diabetes treatment. Granules’ ANDA No. 219466 had triggered the statutory 30-month stay and the litigation.
The case closed on 16 October 2024 via a consent judgment entered by Judge Colm F. Connolly — just 113 days after filing. Under the consent judgment, Granules expressly agreed that both the ‘526 and ‘877 patents are valid and enforceable, and accepted a permanent injunction preventing it from making, using, selling, importing, or distributing its ANDA product until expiry of both patents, including any patent term extension or adjustment. All remaining claims were dismissed without prejudice and without costs to either party.
A resolution in under four months is notably swift even by Hatch-Waxman standards and suggests Granules assessed litigation risk unfavourably — potentially after reviewing claim scope, prosecution history, or prior failed challenges to these patents. The public record does not disclose whether a confidential licence or authorised-generic agreement accompanies the consent judgment, which is common in ANDA settlements and would materially affect Granules’ commercial upside. The absence of a costs award is consistent with a negotiated exit rather than a contested defeat.
Filing to Consent Judgment in 113 days
113 days — faster than the median ANDA Hatch-Waxman resolution in Delaware District Court
Consent judgment entered: what the Granules India order means for both parties
What a consent judgment means in Hatch-Waxman litigation
A consent judgment is a court-ordered agreement where the defendant concedes specified facts and accepts binding relief without a full trial. Here, Granules expressly admitted that both asserted patents are valid and enforceable — a significant concession. The court retains jurisdiction to enforce the order, and any future breach exposes Granules to contempt proceedings in Delaware.
Binding admission of validityBoehringer secures injunction through full patent term
The consent judgment delivers Boehringer its commercially critical objective: Granules’ ANDA product is blocked until both the ‘526 and ‘877 patents expire, including any patent term extension. Boehringer also preserved the right to seek court modification if it obtains additional regulatory exclusivities — a forward-looking protection. No costs were awarded, but the speed and completeness of the win suggests minimal litigation spend.
Full-term market exclusivity protectedGranules’ ANDA blocked; no admitted licence disclosed
Granules accepted an injunction of potentially years in duration and conceded patent validity, foreclosing the ability to re-litigate those questions in this court. Critically, the public record does not confirm whether a confidential authorised-generic or licence arrangement was agreed — a common feature of ANDA consent judgments that could preserve some commercial value for Granules. Absent such a deal, market entry is deferred until patent expiry.
Market entry deferred to patent expiryLinagliptin IP position strengthened against future ANDA filers
Granules’ admission of validity strengthens Boehringer’s litigation posture against any subsequent ANDA challengers to these two patents. Other generic manufacturers monitoring this docket will note that Boehringer obtained a full consent judgment in under four months. For competitors developing linagliptin generics, this outcome signals that challenging the ‘526 and ‘877 patents without strong prior art or validity arguments carries elevated settlement risk.
Higher bar for future generic challengersFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | Pharmaceutical innovator — holder of US9486526B2 and US10034877B2 covering linagliptin tabletsSearch in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Pharma Gmbh & Co., KG | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Granules India Limited | Individual | Granules India Limited — generic pharmaceutical manufacturer seeking ANDA approval for linagliptin 5 mg tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is notable for the breadth of Granules’ concessions: it admits validity and enforceability of both asserted patents by name, accepts an injunction running to expiry including term extensions, and waives jurisdictional defences for enforcement actions. The without-prejudice dismissal of all remaining claims is procedurally standard in ANDA consent judgments and does not indicate any weakness in Boehringer’s infringement position — it simply preserves procedural flexibility. The court’s explicit retention of jurisdiction to supervise performance signals that compliance monitoring was a priority for Boehringer.
US9486526B2 & US10034877B2 — linagliptin tablet formulation patents
US9486526B2 (application no. US14/294630) and US10034877B2 (application no. US15/287228) both protect aspects of linagliptin — a DPP-4 inhibitor used to treat type-2 diabetes and marketed as Tradjenta. The patents cover formulations and methods related to the 5 mg tablet dosage form. Their assertion in an ANDA context means Boehringer listed them in the FDA’s Orange Book, triggering mandatory Paragraph IV certification by any generic seeking early entry, and the associated 30-month stay of ANDA approval.
For the branded pharmaceutical sector, Orange Book-listed patents on a high-volume diabetes medication represent substantial commercial value. Linagliptin competes in the DPP-4 inhibitor class alongside sitagliptin and saxagliptin, making generic entry commercially significant for both Boehringer and the generic manufacturer. The consent judgment’s admission of validity now forms part of the public record, which future ANDA challengers and inter partes review petitioners will need to contend with when assessing the litigation risk of challenging either patent.
Should you run an FTO analysis against US9486526B2 and US10034877B2?
Any pharmaceutical developer formulating linagliptin-containing products — including combination tablets, modified-release forms, or alternative dosage strengths — should assess freedom to operate against both Orange Book-listed patents. The consent judgment confirms enforceability and validity, removing the most common defensive arguments. R&D teams working on DPP-4 inhibitor generics or follow-on formulations face meaningful infringement risk if their product falls within the claim scope of either patent.
PatSnap Eureka’s FTO Search Agent can map your formulation against the claim landscapes of US9486526B2 and US10034877B2, identify prosecution history estoppel constraints, and flag related continuation or divisional patents in Boehringer’s linagliptin portfolio. Early FTO analysis reduces the cost of reformulation or design-around work and helps prioritise which Orange Book patents represent the highest litigation exposure before an ANDA is filed.
Run a freedom-to-operate analysis on US10034877B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA linagliptin and DPP-4 inhibitor patent cases in Delaware
These cases involve ANDA patent infringement actions over DPP-4 inhibitor and diabetes drug formulations litigated in Delaware District Court, comparable to this dispute.
What this case signals for the diabetes drug ANDA IP landscape
A sub-120-day consent judgment with patent validity conceded sets a clear precedent for how Boehringer defends its linagliptin franchise.
Early consent signals strong patent position on linagliptin formulations
Granules’ decision to concede validity of both patents within 113 days — before substantive motions practice — suggests either a weak invalidity case or an unfavourable freedom-to-operate assessment. Generic developers targeting linagliptin should conduct thorough prior-art analysis against the ‘526 and ‘877 patents before filing an ANDA with Paragraph IV certifications.
No-costs dismissal may conceal a confidential licence arrangement
ANDA consent judgments without costs and with preservation of Paragraph IV certification rights are frequently paired with undisclosed authorised-generic or licence agreements. The explicit retention of Granules’ Paragraph IV rights in the order — while also imposing an injunction — is structurally consistent with a delayed entry licence. IP teams tracking the linagliptin competitive landscape should monitor Granules’ ANDA status with the FDA.
Boehringer-Ingelheim v Granules — key questions answered
Under the consent judgment, Granules India expressly agreed that both US9486526B2 (the ‘526 Patent) and US10034877B2 (the ‘877 Patent) are valid and enforceable. Granules also accepted a permanent injunction barring it from making, using, selling, or importing its ANDA No. 219466 product until both patents expire, including any patent term extension or adjustment. All remaining claims were dismissed without prejudice and without costs.
Boehringer Ingelheim asserted two patents: US9486526B2 (application US14/294630) and US10034877B2 (application US15/287228), both covering linagliptin 5 mg tablet formulations. Both patents were Orange Book-listed for Tradjenta, triggering the Hatch-Waxman 30-month stay upon Granules’ Paragraph IV certification in ANDA No. 219466.
The ANDA product at issue was Granules India’s application No. 219466 for linagliptin 5 mg tablets — a generic version of Boehringer Ingelheim’s Tradjenta, a DPP-4 inhibitor used to treat type-2 diabetes. The consent judgment defines the ‘Granules ANDA Product’ broadly to include any supplements, amendments, or replacements to that ANDA.
Yes. The consent judgment explicitly preserves Granules’ right to maintain or file a Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) or 21 C.F.R. § 314.94(a)(12) with respect to both the ‘526 and ‘877 patents. However, Granules remains bound by the injunction against commercialising its ANDA product until the patents expire, including any extensions.
The case resolved in 113 days, from filing on 25 June 2024 to closure on 16 October 2024. This is notably fast for a Hatch-Waxman ANDA case in Delaware, which typically proceeds through scheduling orders and claim construction before settlement. The speed suggests Granules assessed its invalidity or non-infringement arguments as insufficient to justify prolonged litigation, consistent with an early commercial or legal decision to concede.
PatSnap Eureka searches patents and litigation data to answer instantly.